Introduction
Low serum vitamin B12 concentrations have been reported in about 10% of older people, and the prevalence increases with age from around 5% at age 65 years to 20% at age 85 years [1] [2] [3] . In older people, individuals presenting with low vitamin B12 concentrations rarely have the classical features of macrocytic anaemia and neuropathy [4] . More commonly, such individuals present with non-specific symptoms of fatigue and cognitive impairment that can be attributed to 'old age'. Some of the uncertainty about the importance of vitamin B12 deficiency relates to the limitations of the standard vitamin B12 assays. Low serum vitamin B12 concentrations do not accurately reflect intracellular vitamin B12 concentrations, and blood levels of homocysteine (tHcy) or methylmalonic acid (MMA) are believed to be more reliable indicators of intracellular vitamin B12 status [2] . About 80% of vitamin B12 circulating in blood is biologically unavailable for most cells; the rest comprises holotranscobalamin (holoTC), which is the part of serum vitamin B12 bound to transcobalamin, the protein that delivers the vitamin to cells in the body [5] and is easily measured [6] .
In a primary care setting, the indications for the measurement of serum vitamin B12 concentrations typically include a history suggestive of pernicious anaemia, poor nutritional status, cognitive impairment, dementia, neuropathy or malabsorption. But although vitamin B12 supplementation is clearly indicated for the treatment of pernicious anaemia or malabsorption associated with low vitamin B12, the relevance of supplementation with vitamin B12 (and other B vitamins) for the treatment of cognitive impairment is uncertain. Because poor nutritional status is common among older people with dementia, as is age-associated decline in the intestinal absorption of vitamin B12, it is not surprising that a substantial proportion of older people with dementia have low serum vitamin B12 concentrations. Nevertheless, it is widely believed that vitamin B12 deficiency accounts for only a small fraction of the reversible causes of dementia in older people [7, 8] . The aim of this study was to assess if objective evidence for cognitive impairment, depression and peripheral neuropathy was associated with low vitamin B12 concentrations and related markers of vitamin B12 status in a population-based study of older people.
Methods

Participants
Participants were recruited from a random sample of people aged 75 years or older living in their own homes and registered with three general practitioners in Banbury, Oxfordshire, England. Individuals who were known to have a terminal illness or were living in institutions were excluded. Eligible participants were invited to participate in the study and those who agreed were asked to provide written informed consent (see Appendix Figure 1 , available online at http://ageing.oxfordjournals.org). Little is known about the reasons for non-participation, but it is likely that the non-responders had a higher proportion with cognitive impairment. The study protocol was approved by the Central Oxford Research Ethics Committee (COREC CO2.219). Individuals who agreed to participate were visited in their own homes by one of two research nurses between March 2003 and April 2004. Participants underwent a structured interview to record medical history, use of medication and neurological symptoms affecting the lower extremities. Cognitive function was assessed using the MiniMental State Examination (MMSE), cognitive impairment being defined as a MMSE score <22/30 [9] . Depression and anxiety were assessed using a version of the Hospital Anxiety and Depression Scale (HAD-d), and probable depression was defined as a score of 11 or more [10] . A brief neurological examination of the lower limbs included bilateral assessment of knee jerks, ankle tendon jerks, joint position sense of the great toe and plantar responses (see Appendix  Table 1 , available online at http://ageing.oxfordjournals.org). Individuals were defined as having neuropathy if they had more than two symptoms of neuropathy and more than two abnormalities detected on neurological examination of their lower limbs (see Appendix Table 1 , available online at http://ageing.oxfordjournals.org). Missing ankle tendon jerks were also analysed separately as a more sensitive marker of peripheral neuropathy.
Venous blood samples were collected and kept chilled (using a cooling box to ensure that the temperature was maintained below 4°C) until the serum was separated at the local hospital laboratory within 2 h of blood collection. Blood was drawn into vacutainers containing EDTA for full blood count and lithium heparin for creatinine and plain tubes for assessment of markers of vitamin status. Serum was separated and stored at -40°C for subsequent measurement of holoTC, tHcy, MMA and folate. To assess intra-individual variability, we selected a 10% random sample (n = 87) of the participants not receiving vitamin B12 injections or B-vitamin supplements (n = 868) for repeat clinical and blood measurements after 3 months. Individuals with serum vitamin B12 concentrations below 133 pmol/l were treated with hydroxycobalamin (1,000 μg intramuscularly/month) for 3 months, after which all clinical and laboratory assessments were repeated within 1-2 weeks after receiving the third injection.
Laboratory methods
Vitamin B12 concentrations were measured at the Horton General Hospital, Banbury, using a Beckman immunoassay that has a reference range of 133-675 pmol/l (180-914 ng/l). Vitamin B12 concentrations were also measured using a Bayer assay at the Department of Clinical Chemistry, Aarhus University Hospital, Aarhus, Denmark. Serum holoTC concentrations were measured at the Clinical Trial Service Unit using a radioimmunoassay (AXIS-Shield ASA, Oslo, Norway) that has a lower reference limit of 40 pmol/l [6] . MMA and tHcy concentrations were measured in the Department of Pharmacology, Bergen, Norway, using stable isotope-dilution capillary gas chromatography-mass spectrometry [11] . Serum folate concentrations were measured using a microbiological assay at the Department of Biochemistry, Trinity College, Dublin, Ireland [12] . Full blood count and creatinine were measured at the Horton General Hospital laboratory in Banbury using standard methods. Individuals identified with low vitamin B12 concentrations also had their intrinsic factor antibodies and parietal cell antibodies measured in the Radcliffe Hospital Trust Immunology laboratory.
Statistical methods
Continuous variables were summarised as means and standard deviations. Individuals with extreme elevations of vita-min B12 (>1,000 pmol/l) or holoTC (>400 pmol/l) or who reported the use of vitamin B12 injections or any B-vitamin supplements were excluded from comparisons of associations of clinical outcomes with measurements of vitamin status. Logistic regression was used to assess associations of cognitive impairment, depression or neuropathy with quartiles of vitamin status after adjustment for age, sex and smoking. T-tests were used to assess the effect of treatment on measurements of vitamin status. One-way random effects analysis of variance models was used to estimate between-and within-person variability, and hence reliability coefficients, in assays of vitamin status in the 87 subjects selected for repeat measurements. Measurements were log transformed so that the normality assumptions were not seriously violated. Measurements from individuals with low vitamin B12 status who received treatment before obtaining replicate measurements were treated as missing at the follow-up visit [13] . Provided that, conditional on baseline measurements, such data are 'missing at random' [13] , a statistical model that includes both the follow-up and baseline measurements will yield unbiased estimates. Table 1 summarises the characteristics of the overall population and of those with and without low serum vitamin B12 concentrations (using the lower cut-off of the laboratory reference range of <133 pmol/l for the Beckman vitamin B12 assay). Low vitamin B12 concentrations were identified in 125 of the 1,000 participants (13%) and were correlated with cognitive impairment and depression. Although symptoms of neuropathy were common in this age group, they were unrelated to low vitamin B12 concentrations. Medications producing gastric hypochlorhydria, such as H 2 -antagonists and proton pump inhibitors, were in common use but were unrelated to low vitamin B12 concentrations. Among the 49 participants who reported having vitamin B12 injections, four had had gastric surgery and three had small bowel surgery; the remainder had been previously identified as having low blood levels of vitamin B12, but few had true pernicious anaemia. There were no differences in the haemo- Table 1 . Characteristics of the total sample (n = 1,000) and of the subgroups with normal (≥133 pmol/l) or low serum vitamin B12 (<133 pmol/l) concentrations *P = 0.04; **P = 0.0025; MMSE, Mini-Mental State Examination; MCV, mean corpuscular volume.
Results
Associations with low vitamin B12 concentrations
All (n = 1,000)
Normal serum vitamin B12 (n = 875) Low serum vitamin B12 (n = 125) globin concentrations between those participants with or without low serum vitamin B12 concentrations, but the group with low levels had a slightly higher mean corpuscular volume (P = 0.0025).
Antibodies
Testing for parietal cell antibodies was undertaken in 95 of the 125 people with low serum vitamin B12 concentrations. Intrinsic factor antibodies were sought only if the parietal cell antibody test was positive. Parietal cell antibodies were found in 13 of the 95 people tested, and intrinsic cell antibodies indicative of pernicious anaemia were identified in 3 of the 13 people.
Distribution and variability of markers of vitamin B12 status Table 2 summarises the distribution and variability of the different biochemical markers of vitamin B12 status. Among the 87 participants randomly selected for replicate measurements, data were not obtained from 7, and 16 had vitamin B12 concentrations <133 pmol/l and were commenced on vitamin B12 treatment. Table 2 shows that the vitamin B12 concentrations measured using the Bayer assay were higher than those measured using the Beckman assay. The reliability coefficients for the two methods were comparable with each other and with those for holoTC, tHcy and MMA. The correlation coefficient between holoTC and total vitamin B12 (Bayer method) was 0.71. that were independent of vitamin B12. There was no significant association of depression or of neuropathy with any of the laboratory measurements. However, there were significant associations of low holoTC and elevated tHcy and elevated MMA concentrations, respectively, with the risk of missing ankle tendon jerks, which are regarded as a sensitive marker of peripheral neuropathy.
Association with cognitive impairment, depression and neuropathy
Effects of treatment with vitamin B12 on laboratory measurements
The effects of vitamin B12 supplementation on biochemical markers of vitamin B12 status among participants identified with low serum vitamin B12 concentrations are summarised in Table 2 in the Appendix (available online at http://ageing. oxfordjournals.org). The data are derived from 100 participants who had a blood sample collected 1-2 weeks after receiving the third intramuscular injection of 1,000 μg of vitamin B12. Treatment was associated with substantial increases in serum vitamin B12 and holoTC concentrations and in substantial reductions in tHcy and MMA concentrations, with a good response to treatment obtained in 99 of the 100 participants treated (data not shown). Treatment with vitamin B12 injections for a 3 month period was not associated with significant changes in any of the clinical variables (data not shown).
Discussion
Low vitamin B12 concentrations were identified in 13% of this free-living population aged 75 years or greater, a finding consistent with other reports from UK population studies of older people [1] [2] [3] . This study showed that people with low vitamin B12 concentrations rarely had Thus, most older individuals identified with low serum vitamin B12 concentrations have either dietary deficiency or poor absorption of food cobalamin due to gastric atrophy, other malabsorption or a combination, rather than having pernicious anaemia [14] [15] [16] . This study showed that low serum vitamin B12 concentrations were associated with symptoms of memory impairment (P = 0.04) and with objective evidence of cognitive impairment. Low vitamin B12 status was associated with a 2-to 4-fold risk of cognitive impairment, after adjustment for age, sex and smoking. The associations of cognitive impairment with holoTC and with metabolites of vitamin B12 (tHcy and MMA) were stronger than those with serum vitamin B12 concentrations. These associations provide support for the suggestion that holoTC, the biologically active fraction of vitamin B12, is a more reliable indicator of intracellular vitamin B12 status than the standard vitamin B12 assay, and the associations were comparable with those assessed using tHcy and MMA. Low serum folate concentrations were also associated with cognitive impairment, as in other studies [17] [18] [19] . Alzheimer's disease and cerebrovascular disease may be linked aetiologically, possibly through elevated blood tHcy concentrations or other mechanisms [17] . However, it is not possible to exclude reverse causality in that low vitamin B12 or folate levels may be an effect rather than a cause of cognitive impairment [17] .
Low holoTC and elevated tHcy and MMA concentrations were significantly associated with absent ankle tendon jerks, a sensitive marker of peripheral neuropathy. In a previous study of 324 patients presenting with polyneuropathy, Saperstein et al. [20] found that evidence of neuropathy was more likely in individuals with low vitamin B12 status. Above the age of 65 years, missing ankle tendon jerks or loss of vibration sense become more frequent with age in asymptomatic people [21, 22] . This probably reflects age-associated loss of peripheral nerve fibres [23] , and our findings raise the possibility that vitamin B12 deficiency may be a contributing factor.
Depression was unrelated to any of the measurements of vitamin B12 status or to folate status. It is possible that the instruments used to assess depression were not sensitive enough to detect an association. In the Rotterdam study [24] , there was an association between low vitamin B12 status and depression, but was only detected in a two-stage assessment involving an initial screen for depressive symptoms, followed by a more detailed clinical evaluation using Diagnostic and Statistical Manual-IV criteria [24] .
Some European countries are considering folic acid fortification of food, but there are concerns about possible masking of vitamin B12 deficiency. Combined fortification with folic acid and vitamin B12 might offer a solution [25] , but before advocating such a strategy, randomised trials of vitamin B12 supplementation are required to assess the clinical and public health significance of low vitamin B12 levels in older people. The lack of improvement in the cognitive function of individuals with low vitamin B12 after 3 months of vitamin B12 supplementation in our study does not exclude a causative relationship; a mechanism linking mild vitamin B12 deficiency with brain damage would probably be long term in nature. Previous trials of vitamin B12 supplementation for prevention of cognitive decline have been too small to address this question [7, 26] . Trials of vitamin B12 supplementation are feasible because oral vitamin B12 has been shown to be effective in normalising blood metabolite levels [27] . The lowest dose of oral vitamin B12 associated with the maximum reduction in serum MMA concentrations was 650 μg/day, and such treatment would be expected to reduce MMA concentrations by one-third [28] . Long-term trials are required to assess the relevance of vitamin B12 for the prevention of cognitive decline in older people.
Key points
• Low serum vitamin B12 concentrations affect about one in six people aged 75 years or older.
• Individuals with vitamin B12 concentrations in the bottom quartile had twice the risk of cognitive impairment compared with those in the top quartile.
• Long-term trials are currently assessing the effects of high-dose oral vitamin B12 and folic acid on the risk of vascular disease, and some may also assess their relevance for cognitive function.
• Further trials of high-dose oral vitamin B12 without added folic acid are required to assess the relevance of vitamin B12 supplementation for prevention of dementia in older people.
Introduction
Physical function is central to most of our activities. Our physical efficiency permeates all aspects of our life, and it becomes a constraining factor in what we can do, and in turn it can define our quality of life. There is broad evidence that a physically active lifestyle is associated with improvements in functional abilities and health status and that it may prevent certain diseases or diminish their severity [1, 2] . Consequently, the World Health Organization defines active ageing as one important factor to optimise health and to enhance quality of life, and it promotes physically active lifestyles in older adults [3, 4] . Previous research has shown the age-related impairments of and the benefits of physical activity on motor functions [5, 6] . Many of these articles on healthy older adults
